This Article Full Text Full Text (PDF) All Versions of this Article: 0148607108331176v1 33/4/444    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by McClave, S. A. Articles by Wischmeyer, P. E. PubMed PubMed Citation Articles by McClave, S. A. Articles by Wischmeyer, P. E. Social Bookmarking                         What's this?

Comment On: Probiotic Prophylaxis in Predicted Severe Acute Pancreatitis: A Randomized, Double-Blind, Placebo-Controlled Trial

Division of Gastroenterology/Hepatology, University of Louisville, Kentucky

Daren K. Heyland, MD

Department of Medicine, Queen's University, Kingston, Ontario, Canada

Paul E. Wischmeyer, MD

Department of Anesthesia, University of Colorado Health Sciences Center, Aurora, Colorado

BACKGROUND: Infectious complications and associated mortality are a major concern in acute pancreatitis. Enteral administration of probiotics could prevent infectious complications, but convincing evidence is scarce. Our aim was to assess the effects of probiotic prophylaxis in patients with predicted severe acute pancreatitis. METHODS: In this multicentre randomised, double-blind, placebo-controlled trial, 298 patients with predicted severe acute pancreatitis (Acute Physiology and Chronic health Evaluation [APACHE II] score > or =8, Imrie score > or =3, or C-reactive protein >150 mg/L) were randomly assigned within 72 h of onset of symptoms to receive a multispecies probiotic preparation (n = 153) or placebo (n = 145), administered enterally twice daily for 28 days. The primary endpoint was the composite of infectious complications—ie, infected pancreatic necrosis, bacteraemia, pneumonia, urosepsis, or infected ascites—during admission and 90-day follow-up. Analyses were by intention to treat. This study is registered, number ISRCTN38327949. FINDINGS: One person in each group was excluded from analyses because of incorrect diagnoses of pancreatitis; thus, 152 individuals in the probiotics group and 144 in the placebo group were analysed. Groups were much the same at baseline in terms of patients' characteristics and disease severity. Infectious complications occurred in 46 (30%) patients in the probiotics group and 41 (28%) of those in the placebo group (relative risk 1.06, 95% CI 0.75-1.51). 24 (16%) patients in the probiotics group died, compared with nine (6%) in the placebo group (relative risk 2.53, 95% CI 1.22-5.25). Nine patients in the probiotics group developed bowel ischaemia (eight with fatal outcome), compared with none in the placebo group (p = 0.004). INTERPRETATION: In patients with predicted severe acute pancreatitis, probiotic prophylaxis with this combination of probiotic strains did not reduce the risk of infectious complications and was associated with an increased risk of mortality. Probiotic prophylaxis should therefore not be administered in this category of patients. (Lancet. 2008;371:651-659)

Besselink MG, van Santvoort HC, Buskens E, et al; Dutch Acute Pancreatitis Study Group

This version was published on July 1, 2009

Journal of Parenteral and Enteral Nutrition, Vol. 33, No. 4, 444-446 (2009)
DOI: 10.1177/0148607108331176


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?